Compared with WT-HFCFD mice, WT-HFCFD-FMT mice presented significantly lower serum ALT and AST levels, hepatic steatosis, hepatocellular ballooning, and hepatic TG and Chol contents (Figure 2B–F; Figure S2G–J; Table A2). The gene discussed is GPT; the disease is Hepatic steatosis.